VAC045: A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine Candidates

Sponsor

University of Oxford (Other)

Overall Status

Completed

CT.gov ID

NCT01623557

Collaborator

(none)

Enrollment

Locations

Arms

Duration (Months)

Patients Per Site

1.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study aims to assess the safety and effectiveness of four new candidate malaria vaccines; ChAd63 CS, ChAd63 ME-TRAP, MVA CS & MVA ME-TRAP. These vaccines consist of viruses (ChAd63 and MVA) which have been genetically modified so (i) they cannot replicate in humans and (ii) they include parts of the malaria parasite; Plasmodium falciparum (CS and ME-TRAP). The hope is that these vaccines will induce immune responses in vaccinees that are able to prevent malaria.

This proposed study will compare how effective ChAd63-MVA CS is at preventing malaria infection in UK volunteers following malaria challenge compared to ChAd63-MVA ME-TRAP.

The study will be conducted at the University of Oxford's Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford, UK and the Wellcome Trust Clinical Research Facility in Southampton, UK. The malaria challenge will take place at the insectary at Imperial College (Infection and Immunity Section) in London, UK.

Condition or Disease	Intervention/Treatment	Phase
Plasmodium Falciparum Malaria	Biological: ChAd63-MVA CS Biological: ChAd63-MVA ME-TRAP Other: Controlled Human Malaria Infection Administered by Mosquito Bite	Phase 1/Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

30 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Basic Science

Official Title:

A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-Boost Malaria Vaccine Candidates: ChAd63 and MVA Encoding ME-TRAP and the Same Viral Vectors Encoding CS

Study Start Date :

Apr 1, 2012

Actual Primary Completion Date :

Nov 1, 2012

Actual Study Completion Date :

Nov 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Group 1: ChAd63-MVA CS 1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.	Biological: ChAd63-MVA CS 1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later. Other: Controlled Human Malaria Infection Administered by Mosquito Bite Approximately 3 weeks post MVA dosing
Active Comparator: Group 2: ChAd63-MVA ME-TRAP 1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.	Biological: ChAd63-MVA ME-TRAP 1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later. Other: Controlled Human Malaria Infection Administered by Mosquito Bite Approximately 3 weeks post MVA dosing
Active Comparator: Group 3: Unvaccinated Infectivity Controls	Other: Controlled Human Malaria Infection Administered by Mosquito Bite Approximately 3 weeks post MVA dosing

Arm

Intervention/Treatment

Active Comparator: Group 1: ChAd63-MVA CS

1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.

Biological: ChAd63-MVA CS

1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.

Other: Controlled Human Malaria Infection Administered by Mosquito Bite

Approximately 3 weeks post MVA dosing

Active Comparator: Group 2: ChAd63-MVA ME-TRAP

1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.

Biological: ChAd63-MVA ME-TRAP

1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.

Other: Controlled Human Malaria Infection Administered by Mosquito Bite

Approximately 3 weeks post MVA dosing

Active Comparator: Group 3: Unvaccinated Infectivity Controls

Other: Controlled Human Malaria Infection Administered by Mosquito Bite

Approximately 3 weeks post MVA dosing

Outcome Measures

Primary Outcome Measures

The effectiveness of ChAd63-MVA CS and ChAd63-MVA ME-TRAP at preventing malaria infection [Up to 30 days post challenge]
Comparison of the number of individuals who develop malaria infection between vaccinees and unvaccinated control volunteers.

Secondary Outcome Measures

The safety and immunogenicity of ChAd63-MVA CS and ChAd63-MVA ME-TRAP [up to 7 months post first vaccination]
The safety of the vaccine regimens will be assessed by analysing actively and passively collected data from clinical review of volunteers and laboratory measurements. The ability of the vaccines to induce malaria-specific immune responses (immunogenicity) will be assessed by the following laboratory tests; (A) Interferon gamma ELISPOT. (B) Flow cytometry to measure T cell responses Other laboratory investigations including microarray analysis may be performed.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 45 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Healthy adults aged 18 to 45 years.
Able and willing (in the Investigator's opinion) to comply with all study requirements.
Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner.
Women only: Must practice continuous effective contraception for the duration of the study.
Agreement to refrain from blood donation during the course of the study and for at least 3 years after the end of their involvement in the study.
Written informed consent to participate in the trial.
Reachable (24/7) by mobile phone during the period between CHMI and completion of antimalarial treatment.
Willingness to take a curative anti-malaria regimen following CHMI.
For volunteers not living in Oxford: agreement to stay in a hotel room close to the trial centre during a part of the study (from at least day 6.5 post mosquito bite until anti-malarial treatment is completed).
Answer all questions on the informed consent quiz correctly.

Exclusion Criteria:

History of clinical malaria (any species).
Travel to a malaria endemic region during the study period or within the preceding six months with significant risk of malaria exposure.
Use of systemic antibiotics with known antimalarial activity within 30 days of CHMI (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and azithromycin)
Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period.
Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the trial data.
Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed).
Use of immunoglobulins or blood products within 3 months prior to enrolment.
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine (e.g. egg products, Kathon) or malaria infection.
Any history of anaphylaxis post vaccination.
History of clinically significant contact dermatitis.
History of sickle cell anaemia, sickle cell trait, thalassemia or thalassemia trait or any haematological condition that could affect susceptibility to malaria infection.
Pregnancy, lactation or intention to become pregnant during the study.
Contraindications to the use of all three proposed anti-malarial medications; Malarone, Riamet and Chloroquine.
History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
History of serious psychiatric condition that may affect participation in the study.
Any other serious chronic illness requiring hospital specialist supervision.
Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week.
Suspected or known injecting drug abuse in the 5 years preceding enrolment.
Seropositive for hepatitis B surface antigen (HBsAg).
Seropositive for hepatitis C virus (antibodies to HCV) with positive PCR for hepatitis C at screening.
An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system.76
Positive family history in 1st and 2nd degree relatives < 50 years old for cardiac disease.
Volunteers unable to be closely followed for social, geographic or psychological reasons.
Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination.
Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Centre for Clinical Vaccinology and Tropical Medicine	Oxford	Oxfordshire	United Kingdom	OX3 7LE
2	Infection and Immunity Section, Imperial College of Science, Technology and Medicine	London		United Kingdom	SW7 2AZ
3	Wellcome Trust CRF, Southampton General Hospital	Southampton		United Kingdom	SO16 6YD